Cargando…

Dose Dependent Effects on Cell Cycle Checkpoints and DNA Repair by Bendamustine

Bendamustine (BDM) is an active chemotherapeutic agent approved in the U. S. for treating chronic lymphocytic leukemia and non-Hodgkin lymphoma. Its chemical structure suggests it may have alkylator and anti-metabolite activities; however the precise mechanism of action is not well understood. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beeharry, Neil, Rattner, Jerome B., Bellacosa, Alfonso, Smith, Mitchell R., Yen, Timothy J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3386996/ https://www.ncbi.nlm.nih.gov/pubmed/22768280 http://dx.doi.org/10.1371/journal.pone.0040342

Ejemplares similares

Illuminating the route of precision medicine and inhibitor discovery: real-time measurement of DNA repair capacity with molecular beacons
por: Bellacosa, Alfonso, et al.
Publicado: (2018)

Active DNA demethylation—The epigenetic gatekeeper of development, immunity, and cancer
por: Prasad, Rahul, et al.
Publicado: (2020)

Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions
por: Beeharry, Neil, et al.
Publicado: (2015)

Immunological reactions induced by bendamustine
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia
por: Robak, Tadeusz, et al.
Publicado: (2016)

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial
por: Pott, Christiane, et al.
Publicado: (2019)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Bendamustine Associated with Irreversible Ascending Paralysis
por: Alhafez, Ashraf, et al.
Publicado: (2013)

Lichenoid drug eruption associated with Bendamustine
por: Kusano, Y, et al.
Publicado: (2016)

Complex Relationship between Mismatch Repair Proteins and MBD4 during Immunoglobulin Class Switch Recombination
por: Grigera, Fernando, et al.
Publicado: (2013)

Thymine DNA glycosylase as a novel target for melanoma
por: Mancuso, Pietro, et al.
Publicado: (2019)

Limiting DNA polymerase delta alters replication dynamics and leads to a dependence on checkpoint activation and recombination-mediated DNA repair
por: Koussa, Natasha C., et al.
Publicado: (2021)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

DNA double-strand breaks with 5′ adducts are efficiently channeled to the DNA2-mediated resection pathway
por: Tammaro, Margaret, et al.
Publicado: (2016)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Role of bendamustine in the treatment of chronic lymphocytic leukemia
por: Jamshed, Saad, et al.
Publicado: (2009)

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites
por: Darwish, Mona, et al.
Publicado: (2015)

Herpetic esophagitis following bendamustine-containing regimen
por: Yamane, Hiromichi, et al.
Publicado: (2016)

Inhibition of STAT3 by Anticancer Drug Bendamustine
por: Iwamoto, Kazunori, et al.
Publicado: (2017)

Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
por: Stokes, Jessica, et al.
Publicado: (2021)

Reduced bendamustine for elderly patients with follicular lymphoma
por: Masamoto, Yosuke, et al.
Publicado: (2021)

Bendamustine and pneumocystis pneumonia: A systematic review
por: Hakamifard, Atousa, et al.
Publicado: (2022)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Germline mutations in DNA repair and cell cycle checkpoint genes: consequential somatic gene alterations and genome instability
por: Ingvarsson, S
Publicado: (2003)

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
por: de Vos, S, et al.
Publicado: (2018)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
por: López-Iglesias, Ana-Alicia, et al.
Publicado: (2017)

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
por: Modi, Prexy, et al.
Publicado: (2017)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Severe Dermatologic Reactions with Bendamustine: A Case Series
por: Carilli, Allison, et al.
Publicado: (2014)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Skin testing with bendamustine: what concentration should be used?
por: Malinauskiene, Laura, et al.
Publicado: (2020)

Bendamustine/dexamethasone/rituximab: Cytomegalovirus reactivation : case report
Publicado: (2021)

Bendamustine/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Bendamustine/rituximab: Neutropenia, fever and inflammation: case report
Publicado: (2022)

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study
por: Yamasaki, Satoshi, et al.
Publicado: (2021)

Focus-ING on DNA Integrity: Implication of ING Proteins in Cell Cycle Regulation and DNA Repair Modulation
por: Archambeau, Jérôme, et al.
Publicado: (2019)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_58d5f30el1uj8bo2dbgr2bh2gq